ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Merck To Pay $321.6 Million Fine For Illegal Marketing Of Vioxx

DOW JONES NEWSWIRES A U.S. district court judge in Boston ordered Merck & Co. (MRK) to pay a $321.6 million criminal fine for its violation of a federal drug law in connection with its marketing of the former painkiller Vioxx. In December, Merck pleaded guilty to violating the Federal Food, Drug, and Cosmetic Act for introducing a misbranded drug into interstate commerce. The company said it previously recorded a $950 million charge in October 2010 in anticipation of the settlement, which resolves a seven-year investigation. Merck withdrew Vioxx from the market in 2004 after it was linked to a higher risk of heart attacks and strokes. "The government recognized Merck's full cooperation with its investigation and by putting this long-standing investigation to rest, we can more fully focus on discovering, developing and providing innovative medicines and vaccines that save and improve lives around the world," Merck said in a statement. In November, Merck had agreed to pay $950 million and plead guilty to a misdemeanor charge of marketing a misbranded drug, to resolve government allegations that the company illegally promoted Vioxx and deceived the government about the drug's safety. The government alleged that Merck promoted Vioxx for treatment of rheumatoid arthritis before that use was approved by regulators. A portion of the $950 million settlement also was to resolve parallel civil allegations that Merck made false and misleading statements about Vioxx's safety, causing government health programs to pay for the drug's use. Merck denied the civil allegations. Shares were off 14 cents to $38.26 in recent trading. The stock is up 1.5% since the start of the year. -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
03/27/201509:19:49Ebola vaccine candidates pass safety test in in Liberia trials
03/27/201508:00:00Merck to Hold First-Quarter 2015 Sales and Earnings Conference...
03/27/201507:58:02Is This Tiny Biotech Still a Buy at All-Time Highs?
03/26/201508:30:00Merck Announces Collaboration with the American Diabetes Association...
03/25/201519:09:32Investors Scoop Up Companies' Bonds
03/25/201508:48:22Merck's Dividend Has Recovered From Pre-Recession Problems
03/25/201506:30:55Wall Street Breakfast: Kraft, Heinz Announce Mega Merger
03/24/201517:58:29Merck Increases Buyback Authorization by $10 Billion
03/24/201517:00:00Merck Announces New $10 Billion Share Repurchase Program
03/24/201509:08:25Merck's Keytruda tops Bristol-Myers' Yervoy in melanoma trial
03/24/201508:30:00Merckâs Pivotal KEYNOTE-006 Study in First-Line Treatment for A...
03/22/201511:01:043 Things You Need to Know About Achillion Pharmaceuticals Inc.
03/21/201508:11:01Why Pfizer Inc. Isn't Built to Last
03/20/201510:02:00Award-Winning Actress S. Epatha Merkerson and Merck Challenge...
03/18/201516:19:00New Data Investigating Merckâs KEYTRUDA® (pembrolizumab) in Ad...
03/18/201507:59:02Why I'm Not Giving Up on This Tiny Biotech Stock (Yet)
03/18/201507:30:49Trend Is Not Your Friend - Cramer's Mad Money (3/17/15)
03/16/201517:01:01The $136 Billion Cost of Hepatitis C Treatment
03/16/201515:30:00New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN®...
03/16/201511:37:50Why Advaxis, Inc. Stock Ripped Higher Today

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad